Therefore, based on our study, TYK2 did not impact COVID-19 outcome or the autoimmune regulatory mechanism that can be defined in MIS-C, but studies are ongoing, and other regulatory pathways could be found. This evidence concerns the gene TYK2 and COVID-19.